RU2006138704A - Модуляция производства иммуноглобулина и атопические расстройства - Google Patents
Модуляция производства иммуноглобулина и атопические расстройства Download PDFInfo
- Publication number
- RU2006138704A RU2006138704A RU2006138704/14A RU2006138704A RU2006138704A RU 2006138704 A RU2006138704 A RU 2006138704A RU 2006138704/14 A RU2006138704/14 A RU 2006138704/14A RU 2006138704 A RU2006138704 A RU 2006138704A RU 2006138704 A RU2006138704 A RU 2006138704A
- Authority
- RU
- Russia
- Prior art keywords
- reaction chain
- involving
- agonist
- ige
- polypeptide
- Prior art date
Links
- 208000012657 Atopic disease Diseases 0.000 title claims 16
- 230000016784 immunoglobulin production Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims 44
- 238000006243 chemical reaction Methods 0.000 claims 28
- 239000000556 agonist Substances 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 7
- 208000006673 asthma Diseases 0.000 claims 6
- 208000010668 atopic eczema Diseases 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 5
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 102000004527 Interleukin-21 Receptors Human genes 0.000 claims 3
- 108010017411 Interleukin-21 Receptors Proteins 0.000 claims 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims 3
- 208000024780 Urticaria Diseases 0.000 claims 3
- 230000000172 allergic effect Effects 0.000 claims 3
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- 208000010216 atopic IgE responsiveness Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57240704P | 2004-05-19 | 2004-05-19 | |
| US60/572,407 | 2004-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006138704A true RU2006138704A (ru) | 2008-06-27 |
Family
ID=35428852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006138704/14A RU2006138704A (ru) | 2004-05-19 | 2005-05-19 | Модуляция производства иммуноглобулина и атопические расстройства |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20060024268A1 (enExample) |
| EP (1) | EP1753458A4 (enExample) |
| JP (1) | JP2008501042A (enExample) |
| KR (1) | KR20070014181A (enExample) |
| CN (1) | CN1980698A (enExample) |
| AU (1) | AU2005244942A1 (enExample) |
| BR (1) | BRPI0510996A (enExample) |
| CA (1) | CA2566333A1 (enExample) |
| EC (1) | ECSP067014A (enExample) |
| IL (1) | IL179243A0 (enExample) |
| MX (1) | MXPA06013483A (enExample) |
| NO (1) | NO20065487L (enExample) |
| RU (1) | RU2006138704A (enExample) |
| WO (1) | WO2005112983A2 (enExample) |
| ZA (1) | ZA200609600B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| JP4776228B2 (ja) * | 2002-07-15 | 2011-09-21 | ワイス・エルエルシー | Ｔヘルパー（ｔｈ）細胞の発生および機能を調節するための方法および組成物 |
| US7495085B2 (en) | 2003-03-14 | 2009-02-24 | Wyeth | Antibodies against human or mouse IL-21 receptor |
| ZA200507235B (en) * | 2003-03-21 | 2007-03-28 | Wyeth Corp | Treating immunological disorders using agonists of interleukin-21/interleukin-21 receptor |
| AU2004275871A1 (en) * | 2003-09-25 | 2005-04-07 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| ES2428358T3 (es) * | 2003-10-17 | 2013-11-07 | Novo Nordisk A/S | Terapia de combinación |
| KR20070057789A (ko) * | 2004-08-05 | 2007-06-07 | 와이어쓰 | 인터루킨-21 수용체 활성의 상쇄 |
| GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| WO2006111524A2 (en) | 2005-04-18 | 2006-10-26 | Novo Nordisk A/S | Il-21 variants |
| AU2006256802A1 (en) * | 2005-06-06 | 2006-12-14 | Novo Nordisk A/S | Stabilised IL-21 compositions |
| US7914574B2 (en) * | 2005-08-02 | 2011-03-29 | Reva Medical, Inc. | Axially nested slide and lock expandable device |
| ES2491118T3 (es) | 2005-11-28 | 2014-09-05 | Zymogenetics, Inc. | Antagonistas de IL-21 |
| WO2007114861A2 (en) * | 2005-11-28 | 2007-10-11 | Zymogenetics, Inc. | Il-21 receptor antagonists |
| CN101553501A (zh) | 2006-10-26 | 2009-10-07 | 诺沃-诺迪斯克有限公司 | Il-21变种 |
| CA2671665A1 (en) * | 2006-12-21 | 2008-06-26 | Novo-Nordisk A/S | Interleukin-21 variants with altered binding to the il-21 receptor |
| PT2217268T (pt) | 2007-12-07 | 2016-07-28 | Zymogenetics Inc | Anticorpos monoclonais anti-il-21 humana |
| AR071885A1 (es) * | 2008-05-23 | 2010-07-21 | Wyeth Corp | Proteinas de union al receptor de interleuquina 21 |
| BRPI0912998A2 (pt) * | 2008-05-23 | 2015-10-13 | Wyeth Llc | métodos de tratamento que utilizam proteínas de ligação do receptor para a interleucina-21 |
| EP2344180A2 (en) * | 2008-09-23 | 2011-07-20 | Wyeth LLC | Methods for predicting production of activating signals by cross-linked binding proteins |
| WO2010119307A1 (en) * | 2009-04-14 | 2010-10-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for stimulating antigen-specific t cell responses using accelerated co-cultured dendritic cells |
| WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
| JP6395379B2 (ja) | 2011-01-18 | 2018-09-26 | バイオニズ リミテッド ライアビリティー カンパニー | γｃサイトカイン活性を調節するための組成物および方法 |
| CN105579470B (zh) | 2013-06-27 | 2021-05-25 | 莫纳什大学 | Il-21结合蛋白和其用途 |
| WO2016094962A1 (en) | 2014-12-19 | 2016-06-23 | Monash University | Il-21 antibodies |
| US11400134B2 (en) | 2015-10-09 | 2022-08-02 | Bioniz, Llc | Modulating gamma-c-cytokine activity |
| US11709169B2 (en) * | 2017-02-07 | 2023-07-25 | National Jewish Health | Lipid abnormalities and association with atopic allergic diseases |
| US12030936B2 (en) | 2019-05-03 | 2024-07-09 | Bioniz Therapeutics, Inc. | Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4634665A (en) * | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4475196A (en) * | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) * | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) * | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) * | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4510245A (en) * | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4487603A (en) * | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) * | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4596556A (en) * | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4968615A (en) * | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4737323A (en) * | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4987071A (en) * | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) * | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE3883899T3 (de) * | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US4941880A (en) * | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) * | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| EP0705614B1 (en) * | 1989-04-28 | 2002-09-25 | Riker Laboratories, Inc. | Dry powder inhalation device |
| US5034413A (en) * | 1989-07-27 | 1991-07-23 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
| US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) * | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5399677A (en) * | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
| SE9502800D0 (sv) * | 1995-08-10 | 1995-08-10 | Astra Ab | Disposable inhaler |
| US20030143204A1 (en) * | 2001-07-27 | 2003-07-31 | Lewis David L. | Inhibition of RNA function by delivery of inhibitors to animal cells |
| US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| US7189400B2 (en) * | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| US20030212022A1 (en) * | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
| CA2420992C (en) * | 2000-04-05 | 2010-07-13 | Zymogenetics, Inc. | Soluble zalpha11 cytokine receptors |
| CA2312142A1 (en) * | 2000-06-22 | 2001-12-22 | An-Go-Gen Inc. | Injection system for gene delivery |
| WO2003040313A2 (en) * | 2001-11-05 | 2003-05-15 | Zymogenetics, Inc | Il-21 antagonists |
| EP1572902B1 (en) * | 2002-02-01 | 2014-06-11 | Life Technologies Corporation | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| WO2003093430A2 (en) * | 2002-05-03 | 2003-11-13 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for use in preparing sirnas |
| CN1685063B (zh) * | 2002-08-12 | 2011-12-21 | 新英格兰生物实验室公司 | 与基因沉默相关的方法和组合物 |
| PL376118A1 (en) * | 2002-10-11 | 2005-12-12 | Novo Nordisk A/S | Treatment of allergic conditions by use of il 21 |
| US7495085B2 (en) * | 2003-03-14 | 2009-02-24 | Wyeth | Antibodies against human or mouse IL-21 receptor |
| ZA200507235B (en) * | 2003-03-21 | 2007-03-28 | Wyeth Corp | Treating immunological disorders using agonists of interleukin-21/interleukin-21 receptor |
| GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis |
-
2005
- 2005-05-19 CA CA002566333A patent/CA2566333A1/en not_active Abandoned
- 2005-05-19 KR KR1020067024218A patent/KR20070014181A/ko not_active Withdrawn
- 2005-05-19 RU RU2006138704/14A patent/RU2006138704A/ru not_active Application Discontinuation
- 2005-05-19 JP JP2007527432A patent/JP2008501042A/ja not_active Withdrawn
- 2005-05-19 WO PCT/US2005/017514 patent/WO2005112983A2/en not_active Ceased
- 2005-05-19 EP EP05779552A patent/EP1753458A4/en not_active Withdrawn
- 2005-05-19 BR BRPI0510996-5A patent/BRPI0510996A/pt not_active IP Right Cessation
- 2005-05-19 CN CNA2005800162359A patent/CN1980698A/zh not_active Withdrawn
- 2005-05-19 MX MXPA06013483A patent/MXPA06013483A/es unknown
- 2005-05-19 AU AU2005244942A patent/AU2005244942A1/en not_active Withdrawn
- 2005-05-19 US US11/132,947 patent/US20060024268A1/en not_active Abandoned
-
2006
- 2006-11-13 IL IL179243A patent/IL179243A0/en unknown
- 2006-11-17 ZA ZA200609600A patent/ZA200609600B/xx unknown
- 2006-11-17 EC EC2006007014A patent/ECSP067014A/es unknown
- 2006-11-28 NO NO20065487A patent/NO20065487L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1753458A2 (en) | 2007-02-21 |
| CA2566333A1 (en) | 2005-12-01 |
| MXPA06013483A (es) | 2007-01-23 |
| JP2008501042A (ja) | 2008-01-17 |
| EP1753458A4 (en) | 2009-07-22 |
| AU2005244942A1 (en) | 2005-12-01 |
| WO2005112983A3 (en) | 2006-10-05 |
| CN1980698A (zh) | 2007-06-13 |
| KR20070014181A (ko) | 2007-01-31 |
| WO2005112983A2 (en) | 2005-12-01 |
| US20060024268A1 (en) | 2006-02-02 |
| ECSP067014A (es) | 2006-12-29 |
| NO20065487L (no) | 2006-12-18 |
| BRPI0510996A (pt) | 2007-12-04 |
| IL179243A0 (en) | 2007-03-08 |
| ZA200609600B (en) | 2010-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006138704A (ru) | Модуляция производства иммуноглобулина и атопические расстройства | |
| JP2008501042A5 (enExample) | ||
| Pellesi et al. | Spotlight on anti‐CGRP monoclonal antibodies in migraine: The clinical evidence to date | |
| Russo | Calcitonin gene-related peptide (CGRP): a new target for migraine | |
| Wu et al. | Autocrine interleukin-10 mediates glucagon-like peptide-1 receptor-induced spinal microglial β-endorphin expression | |
| Van der Velden et al. | Autonomic innervation of human airways: structure, function, and pathophysiology in asthma | |
| Sánchez et al. | Role of neural NO synthase (nNOS) uncoupling in the dysfunctional nitrergic vasorelaxation of penile arteries from insulin-resistant obese Zucker rats | |
| Šiprová et al. | Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat? | |
| Giamberardino et al. | Anti-CGRP monoclonal antibodies in migraine: current perspectives | |
| Barson et al. | Substance P in the anterior thalamic paraventricular nucleus: promotion of ethanol drinking in response to orexin from the hypothalamus | |
| Rokugo et al. | A histochemical study of substance P in the rat spinal cord: effect of transcutaneous electrical nerve stimulation | |
| Pineda‐Farias et al. | The l‐kynurenine–probenecid combination reduces neuropathic pain in rats | |
| Laorden et al. | Effects of morphine and morphine withdrawal on brainstem neurons innervating hypothalamic nuclei that control thepituitary‐adrenocortical axis in rats | |
| Christophidis et al. | Growth hormone receptor immunoreactivity is increased in the subventricular zone of juvenile rat brain after focal ischemia: A potential role for growth hormone in injury-induced neurogenesis | |
| Schultz et al. | VGLUT1 synapses and P‐boutons on regenerating motoneurons after nerve crush | |
| Engle et al. | Spinal nerve ligation decreases γ‐aminobutyric acidB receptors on specific populations of immunohistochemically identified neurons in L5 dorsal root ganglion of the rat | |
| Fan et al. | The emerging role of neuroimmune interactions in atopic dermatitis and itch | |
| Wellman et al. | Pharmacologic antagonism of ghrelin receptors attenuates development of nicotine induced locomotor sensitization in rats | |
| RU2008131052A (ru) | Модуляция костеобразования | |
| De Domenico et al. | Modulation of GDF11 expression and synaptic plasticity by age and training | |
| Lewiecki | Monoclonal antibodies for the treatment of osteoporosis | |
| Colloton et al. | Cinacalcet attenuates hypercalcemia observed in mice bearing either Rice H-500 Leydig cell or C26-DCT colon tumors | |
| Takeda et al. | Temporomandibular joint inflammation decreases the voltage-gated K+ channel subtype 1.4-immunoreactivity of trigeminal ganglion neurons in rats | |
| Gaede et al. | Catestatin, a chromogranin A-derived peptide, is sympathoinhibitory and attenuates sympathetic barosensitivity and the chemoreflex in rat CVLM | |
| Batten et al. | Evidence for peptide co-transmission in retrograde-and anterograde-labelled central nucleus of amygdala neurones projecting to NTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100328 |